|
Malignant neoplasm of prostate
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
βKlotho inhibits androgen/androgen receptor‑associated epithelial‑mesenchymal transition in prostate cancer through inactivation of ERK1/2 signaling.
|
29749458 |
2018 |
|
Malignant neoplasm of prostate
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
In sum, our findings reveal a novel AR-coactivator binding mechanism that may have clinical implications for AR activity in prostate cancer.
|
22102282 |
2012 |
|
Malignant neoplasm of prostate
|
1.000 |
Biomarker
|
disease |
BEFREE |
Thus, inhibiting ETV1 or blocking its interaction with AR may represent novel strategies in prostate cancer therapy.
|
19789348 |
2009 |
|
Malignant neoplasm of prostate
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity.
|
16384856 |
2006 |
|
Malignant neoplasm of prostate
|
1.000 |
Biomarker
|
disease |
BEFREE |
PCA3, as a therapeutic target in PCa, might be used to potentiate AR antagonists.
|
28668854 |
2017 |
|
Malignant neoplasm of prostate
|
1.000 |
Biomarker
|
disease |
BEFREE |
Therefore, this review aims to summarize the tumor microenvironment and its impact on androgen receptor signaling in prostate cancer.
|
30528321 |
2019 |
|
Malignant neoplasm of prostate
|
1.000 |
Biomarker
|
disease |
BEFREE |
Furthermore, ADT combined with vaccination, specifically a DNA vaccine encoding the ligand-binding domain of the AR, led to improved antitumor responses as measured by tumor volumes and delays in the emergence of castrate-resistant prostate tumors in two murine prostate cancer models (Myc-CaP and prostate-specific PTEN-deficient mice).
|
29051161 |
2017 |
|
Malignant neoplasm of prostate
|
1.000 |
Biomarker
|
disease |
BEFREE |
The major topic areas discussed at this year's meeting included (a) new insights into prostate cancer biology and treatment; (b) approaches for accelerating precision medicine for prostate cancer; (c) prostate-specific membrane antigen-targeted therapy and imaging for prostate cancer; (d) updates on Poly (ADP-ribose) polymerase (PARP)-inhibitor clinical trial results; (e) the biology and role of prostate cancer stem cells; (f) new approaches for targeting the androgen receptor and other steroid hormone receptor pathways; (g) racial disparities in prostate cancer treatment and outcomes; (h) the role of the nervous system in prostate cancer development and progression; (i) the role of the WNT signaling pathway in normal prostate and prostate cancer biology; (j) novel immunotherapy approaches; and (k) the ecology of prostate cancer.
|
31334865 |
2019 |
|
Malignant neoplasm of prostate
|
1.000 |
Biomarker
|
disease |
BEFREE |
Activation of β-catenin signaling in androgen receptor-negative prostate cancer cells.
|
22298898 |
2012 |
|
Malignant neoplasm of prostate
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
ARD-69 is capable of reducing the AR protein level by >95% in these prostate cancer cell lines and effectively suppressing AR-regulated gene expression.
|
30629437 |
2019 |
|
Malignant neoplasm of prostate
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Despite the AR being one of the most studied and attended targets in cancer, those gain-of-function mutations in the receptor remain a significant challenge for the development of PCa therapies.
|
31698174 |
2019 |
|
Malignant neoplasm of prostate
|
1.000 |
Biomarker
|
disease |
BEFREE |
Here, we show that loss of the PTEN tumor suppressor gene is associated with hyperactivation of the AR in human PCa cell lines.
|
19074897 |
2008 |
|
Malignant neoplasm of prostate
|
1.000 |
Biomarker
|
disease |
BEFREE |
These data show that TRPS1 protein expression is regulated by androgens via the AR in human prostate cancer xenografts.
|
15613454 |
2004 |
|
Malignant neoplasm of prostate
|
1.000 |
Biomarker
|
disease |
BEFREE |
Together, these contrasting PTEN effects on AR activity in the same prostate cancer cell line with different passage numbers suggest that PTEN, via distinct mechanisms, differentially regulates AR in various stages of prostate cancers.
|
15205473 |
2004 |
|
Malignant neoplasm of prostate
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
To evaluate the hypothesis that amplification of the AR gene is a cause for the failure of androgen deprivation therapy in prostate cancer, we studied whether AR amplification leads to gene overexpression, whether the amplified AR gene is structurally intact, and whether tumors with AR amplification have distinct biological and clinical characteristics.
|
9000575 |
1997 |
|
Malignant neoplasm of prostate
|
1.000 |
Biomarker
|
disease |
BEFREE |
To assess AR alteration as a mechanism of treatment resistance, a mouse model (h/mAR-TRAMP) was used in which the murine AR coding region is replaced by human sequence and prostate cancer initiated by a transgenic oncogene.
|
19010817 |
2008 |
|
Malignant neoplasm of prostate
|
1.000 |
Biomarker
|
disease |
BEFREE |
Our objective was to generate a novel cell line model representing the endocrine treatment naive prostate cancer for testing treatments that target the androgen receptor (AR) and androgen metabolism.
|
20687225 |
2010 |
|
Malignant neoplasm of prostate
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
We have examined the inhibitory effect of rStd on androgen action in the human prostate cancer-derived PC-3 cells transfected with the rat androgen receptor (AR) expression plasmid and two androgen-responsive promoter reporter constructs (murine mammary tumor long-terminal repeat ligated to chloramphenicol acetyltransferase (CAT) gene and rat probasin androgen response element (ARE) ligated to firefly luciferase (LUC) gene).
|
9566751 |
1998 |
|
Malignant neoplasm of prostate
|
1.000 |
Biomarker
|
disease |
BEFREE |
Taken together, these results suggest that AR-regulated WNT7B signaling is critical for the growth of CRPC and development of the osteoblastic bone response characteristic of advanced prostate cancer.
|
23386686 |
2013 |
|
Malignant neoplasm of prostate
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
We recently demonstrated that a key transcription factor for lipogenesis, sterol regulatory element-binding protein-1 (SREBP-1), induced fatty acid and lipid accumulation and androgen receptor (AR) transcriptional activity, and also promoted prostate cancer cell growth and castration resistance.
|
23951060 |
2013 |
|
Malignant neoplasm of prostate
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
Androgen receptor is a ligand-activated transcription factor and a validated drug target for all stages of prostate cancer.
|
23443807 |
2013 |
|
Malignant neoplasm of prostate
|
1.000 |
Biomarker
|
disease |
BEFREE |
The androgen receptor (AR) plays a key role in prostate cancer development, as well as its treatments, even for the hormone-refractory state.
|
16397271 |
2006 |
|
Malignant neoplasm of prostate
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
We integrated chromatin-immunoprecipitation-coupled sequencing and microarray expression profiling in TMPRSS2-ERG gene rearrangement positive DUCaP cells with the GWAS PCa risk SNPs catalog to identify disease susceptibility SNPs localized within functional androgen receptor-binding sites (ARBSs).
|
26411452 |
2016 |
|
Malignant neoplasm of prostate
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
The A allele of the G1733A polymorphism of the AR gene has been associated with increased risk of prostate cancer.
|
16254899 |
2006 |
|
Malignant neoplasm of prostate
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
An AR variant-driven gene module that is upregulated during human PC progression was identified.
|
30108134 |
2018 |